MedTrace Logo

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

NCT06028425 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-07-22

No results posted yet for this study

Summary

The main purpose of this study is to measure how much of LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered in fasting and fed states in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783. Participation could last up to 63 days including screening period.

Conditions

  • Healthy

Interventions

DRUG

LOXO-783

Administered orally.

Sponsors & Collaborators

Principal Investigators

  • Yingying Guo-Avrutin, MD, PhD · Loxo Oncology, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2023-12-23
Completion
2023-12-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06028425 on ClinicalTrials.gov